Cardiotoxicity: all 269 studies
Page 1 of 3. Open to participants first (71), then studies with results posted, then the rest; newest registration first within each.
- Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)Not yet recruitingNCT07864727
- Cardioprotection Effect of LinagliptinNot yet recruitingNCT07852546Phase 3
- Heart Failure in Women: Epidemiological and Prognostic InsightsRecruitingNCT07847983
- Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced CardiotoxicityNot yet recruitingNCT07838649Phase 1
- Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)Not yet recruitingNCT07776964Not applicable
- Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07761910Phase 2
- Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.RecruitingNCT07663357
- The CARDIOPROTECT TrialRecruitingNCT07654426Phase 2
- Cardiac Side Effects of Systemic Therapy in Early-Stage Breast CancerRecruitingNCT07588425
- Sotagliflozin as Prevention of Anthracycline-Related CardiotoxicityNot yet recruitingNCT07572175Phase 2
- Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer TherapyRecruitingNCT07528586Not applicable
- Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric AgeRecruitingNCT07382141Not applicable
- BRAVE-HEART: Breast Cancer Radiotherapy Using Active Breathing Coordinator to aVoid Exposure of HEARTRecruitingNCT07299812
- Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer PatientsNot yet recruitingNCT07254221Phase 4
- ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted TherapiesRecruitingNCT07191730
- Novel On-body Evaluation of Cardiac Health for OncologyEnrolling by invitationNCT07158450
- Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT07157670
- Artificial Intelligence for Reconstruction of Echocardiography StudiesNot yet recruitingNCT07093918
- JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First YearRecruitingNCT06930521Not applicable
- Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort StudyNot yet recruitingNCT06897189
- Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or TrastuzumabNot yet recruitingNCT06881940Not applicable
- Cardioprotection on Chemotherapy-Induced CardiotoxicityRecruitingNCT06853951Phase 3
- Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With AnthracyclinesRecruitingNCT06774326
- AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable MonitorRecruitingNCT06699056
- Effects of Lurasidone on Left Ventricle Systolic FunctionsNot yet recruitingNCT06695676
- Atorvaststin and Cardiotoxicity in Acute Myloid LeukemiaNot yet recruitingNCT06684509Phase 1/2
- Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic TherapiesRecruitingNCT06664528
- CARDiac Toxicity Following ImmunOtherapy Treatment for MelanomaEnrolling by invitationNCT06605833
- Exercise for Ameliorating Chemotherapy CardiotoxicityNot yet recruitingNCT06595316Not applicable
- Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER StudyRecruitingNCT06595147Not applicable
- Cardiotoxicity of Carbon Monoxide in Patients Treated With Hyperbaric Oxygen TherapyRecruitingNCT06549621
- Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-BRecruitingNCT06443645
- Early Assessment of Cardiac Function After Treatment With CAR-T CellsRecruitingNCT06350994
- Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced CardiotoxicityRecruitingNCT06341842Phase 2
- NT-proBNP to Assess Trastuzumab-induced CardiotoxicityRecruitingNCT06340516Not applicable
- Myocardial Fibrosis Identification in Patients With Anthracycline-induced CardiotoxicityRecruitingNCT06331806Not applicable
- TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by EchocardiographyRecruitingNCT06310330Not applicable
- Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer ChemotherapyRecruitingNCT06282796
- Effects of Exercise Training in Survivors of LymphomaRecruitingNCT06270667Not applicable
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaRecruitingNCT06220032Phase 3
- The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac ToxicityRecruitingNCT06214195Phase 3
- Hypertension and Arrhythmias in CLL Patients Treated With BTK InhibitorsEnrolling by invitationNCT06211413
- The STOP-MED CTRCD TrialRecruitingNCT06183437Phase 4
- Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related CardiotoxicityRecruitingNCT06132984
- A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer PatientsRecruitingNCT06092606Phase 2
- Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride InjectionRecruitingNCT06060132
- Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple MyelomaRecruitingNCT06039735
- A Study of Blood Pressure Control During Cancer TreatmentRecruitingNCT06023576Phase 2
- Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)Not yet recruitingNCT06005259Phase 4
- New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.RecruitingNCT05992337
- Understanding CARdiac Events in Breast CancerRecruitingNCT05921279
- Strategy Therapy on Cancer Therapy-Related Cardiac DysfunctionRecruitingNCT05892146Not applicable
- Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal StudyRecruitingNCT05851053
- Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer PatientsRecruitingNCT05732051Phase 2
- Global Cardio Oncology RegistryRecruitingNCT05598879
- Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 TargetedRecruitingNCT05559164Phase 2
- Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)RecruitingNCT05465031Phase 4
- PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility StudyNot yet recruitingNCT05377320
- COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)RecruitingNCT05258448
- Defining Robust Predictors of Chemotherapy Related CardiotoxicityRecruitingNCT05159479
- The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled TrialRecruitingNCT05023785Not applicable
- Study on Proton Radiotherapy of Thymic MalignanciesRecruitingNCT04822077Not applicable
- Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart FailureRecruitingNCT04262830
- Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity StudyEnrolling by invitationNCT04260269
- Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac DysfunctionRecruitingNCT03934905Phase 1/2
- Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine CareRecruitingNCT03882580
- Cardiac Dysfunction in Childhood Cancer SurvivorsRecruitingNCT03790943
- Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)RecruitingNCT03711110Not applicable
- S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityRecruitingNCT03418961Phase 3
- Evaluation and Management of Cardio Toxicity in Oncologic PatientsRecruitingNCT02818517
- Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer PatientsRecruitingNCT02772367
- Pilot Study of an NTproBNP Guided Strategy of CardioprotectionCompletedNCT04737265Phase 1/2Results posted
- Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or TrastuzumabCompletedNCT04023110Phase 1Results posted
- PROactive Evaluation of Function to Avoid CardioToxicityTerminatedNCT03862131Phase 2Results posted
- Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and VietnamCompletedNCT03355664Phase 3Results posted
- STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)CompletedNCT02943590Phase 2Results posted
- An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast CancerCompletedNCT02696707Phase 4Results posted
- 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerTerminatedNCT02677714Phase 2Results posted
- STOP Heart Disease in Breast Cancer Survivors TrialTerminatedNCT02674204Phase 2Results posted
- Use of Metformin to Reduce Cardiac Toxicity in Breast CancerTerminatedNCT02472353Phase 2Results posted
- Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk StratificationCompletedNCT02177175Phase 2Results posted
- Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent SimvastatinTerminatedNCT02096588Phase 2Results posted
- MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity AddendumCompletedNCT01719562Not applicableResults posted
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving TrastuzumabCompletedNCT01009918Phase 2Results posted
- Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving DoxorubicinCompletedNCT00577798Results posted
- Staccato Prochlorperazine Thorough QT/QTcCompletedNCT00543062Phase 1Results posted
- Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By SurgeryCompletedNCT00436566Phase 2Results posted
- ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-upCompletedNCT07680855
- Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced ElectrocardiographyCompletedNCT07515859
- Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE TrialActive, not recruitingNCT07442578Not applicable
- Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung CancerCompletedNCT07267247
- Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphomaCompletedNCT07041827
- Dapagliflozin to Prevent Anthracycline-Induced CardiotoxicityCompletedNCT06888505Phase 2
- HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed TherapyTerminatedNCT06844669Phase 2
- Optimising Screening for the Cardiotoxic Effects of Cancer TherapyCompletedNCT06817044
- In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer SurvivorsCompletedNCT06778122Not applicable
- Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer PatientsStatus unknownNCT06622954Not applicable
- BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORSStatus unknownNCT06597045
- The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced CardiotoxicityCompletedNCT06478667Phase 3
- Effects of Immune Checkpoint Inhibitors on Coronary MicrovasculatureActive, not recruitingNCT06332131